Mineralys Therapeutics (MLYS) Cash from Investing Activities (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Cash from Investing Activities data on file, last reported at -$44.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 51.61% year-over-year to -$44.9 million; the trailing twelve-month figure through Mar 2026 stood at -$341.8 million (down 538.03% YoY), and the FY2025 full-year result was -$389.8 million, down 439.04% from the prior year.
• Cash from Investing Activities improved to -$44.9 million in Q1 2026, from -$103.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $83.6 million in Q4 2024 to a low of -$150.5 million in Q3 2025.
• A 5-year average of -$33.5 million and a median of -$42.9 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 1886.65% in 2024 and sank 654.3% in 2025, its largest moves.
• Tracing MLYS's Cash from Investing Activities over 5 years: stood at $50.0 million in 2022, then sank by 116.18% to -$8.1 million in 2023, then jumped by 1133.13% to $83.6 million in 2024, then sank by 223.84% to -$103.5 million in 2025, then soared by 56.57% to -$44.9 million in 2026.
• Business Quant data shows MLYS's Cash from Investing Activities at -$44.9 million in Q1 2026, -$103.5 million in Q4 2025, and -$150.5 million in Q3 2025.